A federal judge has ruled that several key restrictions on the abortion drug mifepristone are unlawful, a decision that could reshape access to medication abortion across the United States. The ruling challenges longstanding FDA requirements that mifepristone be dispensed in person and that patients make multiple doctor visits, among other conditions.
Mifepristone, used in combination with misoprostol, is the primary method for medication abortion, accounting for more than half of all US abortions. It was approved by the FDA in 2000 and has a long safety record, but anti-abortion groups have argued that tighter controls are needed to protect women's health.
The judge, appointed by a previous administration, ruled that the FDA's restrictions exceeded its authority and were not based on sound science. The decision applies nationwide unless blocked by higher courts, which is likely given the ongoing legal battle.
Supporters of the ruling say it aligns with current medical evidence that the drug is safe for use without in-person supervision. Critics warn it could lead to unsafe practices and reduce oversight. The case is expected to reach the Supreme Court, adding another chapter to the nation's abortion debate after the 2022 Dobbs decision.
For now, the ruling creates uncertainty for patients and providers. Some clinics may immediately change their protocols, while others will wait for appeals. The practical impact will vary by state, especially in those with additional abortion restrictions.